A phase Ib/IIa clinical study of SYNB1020 in patients with urea cycle disorders (UCD).
Phase of Trial: Phase I/II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs SYNB 1020 (Primary)
- Indications Inborn urea cycle disorders
- Focus Adverse reactions
- 05 Jan 2018 According to a Synlogic media release, this trial is expected to be initiated in mid-2018, with data expected in 2019.
- 27 Jun 2017 New trial record
- 19 Jun 2017 According to a Synlogic media release, company plans to initiate this trial by mid-2018.